Sage Therapeutics reported a significant decrease in net loss and operating costs for the first quarter of 2025 compared to the same period in 2024, driven by cost savings measures. Collaboration revenue from ZURZUVAE saw substantial growth, while ZULRESSO revenue was nil. The company maintains a strong cash position expected to fund operations into mid-2027.

Sage Therapeutics reported a net loss of $95.8 million for the fourth quarter of 2024, an improvement from $32.7 million in the same period of 2023. Collaboration revenue from ZURZUVAE significantly increased to $11.4 million in Q4 2024, up from $0.8 million in Q4 2023, indicating strong initial growth for the new treatment. The company also saw a substantial increase in ZURZUVAE shipments, with nearly 2,500 prescriptions delivered in Q4 2024.

Sage Therapeutics reported encouraging third quarter results, highlighted by continued growth in ZURZUVAE revenue and shipments, and announced a strategic reorganization to support the ongoing launch of ZURZUVAE and focus pipeline development efforts.

Sage Therapeutics reported $7.4 million in ZURZUVAE collaboration revenue, a 19% increase from Q1 2024. Over 1,400 ZURZUVAE prescriptions were shipped and delivered, nearly doubling from the previous quarter. The company's cash, cash equivalents, and marketable securities totaled $647 million as of June 30, 2024. SAGE-324's clinical development for essential tremor was terminated.

Sage Therapeutics reported $6.2 million in ZURZUVAE collaboration revenue and $1.7 million in ZULRESSO revenue for the first quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $717 million as of March 31, 2024.

Sage Therapeutics reported $0.8 million in collaboration revenue from ZURZUVAE in Q4 2023, marking its commercial availability in mid-December. The company achieved a net loss of $32.7 million for the quarter, with cash, cash equivalents, and marketable securities totaling $753 million at year-end.

Sage Therapeutics announced the upcoming commercial launch of ZURZUVAE for postpartum depression, and reported a strong financial foundation with $876 million in cash, cash equivalents and marketable securities as of September 30, 2023. Net revenue from sales of ZULRESSO was $2.7 million. The company expects operations to be supported into 2026, and annualized net savings of approximately $240 million from strategic reorganization.

Sage Therapeutics announced the FDA approval of ZURZUVAE for postpartum depression (PPD) and is preparing for its launch in Q4 2023. The company is disappointed by the Complete Response Letter (CRL) from the FDA regarding zuranolone for major depressive disorder (MDD). The company is evaluating resource allocation, including pipeline prioritization and workforce reorganization, to extend its cash runway.

Sage Therapeutics reported a net revenue of $3.3 million from ZULRESSO sales in Q1 2023, compared to $1.6 million in the same period of 2022. The company's cash, cash equivalents, and marketable securities totaled $1.1 billion as of March 31, 2023. The FDA accepted the filing of an NDA for zuranolone for the treatment of MDD and PPD with a PDUFA action date of August 5, 2023.

Sage Therapeutics reported fourth quarter and full year 2022 financial results, with a focus on advancing the regulatory path for zuranolone in MDD and PPD. The FDA accepted the NDA filing for zuranolone and granted Priority Review. The company's pipeline is progressing with nine studies across neuropsychiatry and neurology in 2023. Year-end cash, cash equivalents, and marketable securities totaled $1.3 billion, expected to support operations into 2025.

Sage Therapeutics reported $1.7 million in net revenue from sales of ZULRESSO in the third quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $1.4 billion as of September 30, 2022, and anticipates operations will be supported into 2025.

Sage Therapeutics reported its Q2 2022 financial results, featuring progress on the NDA submission for zuranolone and advancements in their clinical pipeline. The company's cash is expected to support operations into 2025.

Sage Therapeutics reported its Q1 2022 financial results, highlighted by the initiation of a rolling NDA submission for zuranolone in MDD and progress across its pipeline. The company's cash, cash equivalents, and marketable securities totaled $1.6 billion. Net revenue from ZULRESSO sales was $1.6 million, and the net loss was $122.1 million.

Sage Therapeutics reported business highlights and financial results for the fourth quarter and full year ended December 31, 2021. The company ended the year with a cash balance of $1.7 billion and anticipates ending 2022 with approximately $1.3 billion. A rolling NDA submission for zuranolone in MDD is expected to begin in early 2022.

Sage Therapeutics reported a net revenue of $1.4 million from sales of ZULRESSO in Q3 2021, compared to $1.6 million in the same period of 2020. The company's cash, cash equivalents, and marketable securities totaled $1.8 billion as of September 30, 2021. They are advancing their portfolio of clinical programs, notably zuranolone for MDD and PPD, and planning to file an NDA for zuranolone in the second half of 2022.

Sage Therapeutics reported positive topline data from the pivotal WATERFALL Study of zuranolone in patients with MDD, showing a statistically significant and clinically meaningful reduction in depressive symptoms. The company is advancing its pipeline, including the initiation of Phase 1 program for SAGE-689 and first patient dosed in SAGE-718 PARADIGM Parkinson’s disease Study Part B. Net revenue from sales of ZULRESSO was $1.6 million.

Sage Therapeutics reported a net revenue of $1.6 million from sales of ZULRESSO in Q1 2021, compared to $2.3 million in the same period of 2020. The company's research and development expenses were $58.1 million, and SG&A expenses were $39.8 million. The net loss for the quarter was $95.8 million. The company anticipates having more than $1.7 billion in cash, cash equivalents, and marketable securities at the end of 2021.

Sage Therapeutics reported a net income of $974.9 million for the fourth quarter of 2020, driven by $1.1 billion in net revenue, primarily from a collaboration with Biogen. The company ended the year with a strong cash position of $2.1 billion.

Sage Therapeutics reported $1.6 million in net revenue from sales of ZULRESSO in Q3 2020, compared to $1.5 million for the same period in 2019. The company's clinical programs across three franchises remain on track, with key milestones anticipated over the next 12 to 18 months.

Sage Therapeutics reported $1.1 million in net revenue from ZULRESSO sales for the second quarter of 2020. The company is advancing its pipeline with multiple clinical trials across its depression and neurology franchises. They are initiating a Phase 3 study in patients with advanced COVID-19 related acute respiratory distress syndrome (ARDS).

Sage Therapeutics reported $2.3 million in net revenues from ZULRESSO in Q1 2020 and is advancing its pipeline with several clinical trials planned for zuranolone, SAGE-324, and SAGE-718, while also undergoing corporate restructuring to focus on core programs and reduce costs.

Sage Therapeutics reported $2.0 million in revenues from ZULRESSO sales for the fourth quarter of 2019. The company is evaluating the path forward for the zuranolone (SAGE-217) Landscape Program and plans to continue expanding its Neurology and Neuropsychiatry franchises with additional studies in 2020.